(Total Views: 551)
Posted On: 03/09/2025 3:51:06 PM
Post# of 151530
Cytodyn Jan. 2021 Application for TNBC tumors.
MGK has always clearly pointed out our metastatic triple-negative breast cancer (“mTNBC”) targets the 85% population pool.
While tNBC is the remaining 15%.
Well, 2021 Cytodyn filed too for tNBC.
We are on-deck for the entire apple !!
DETAILED DESCRIPTION
[0019] Although metastasis is the leading cause of death for patients with breast cancer, currently there are no treatments available that are directed to the metastatic process. Thus, better treatments for metastatic cancer, including metastatic breast cancer are needed. Presented herein are methods for treating a subject for metastatic breast cancer by administering to the subject an effective amount of a CCR5 binding agent, such as leronlimab.
0025] As shown in the Examples presented herein, data from the first patient in the Phase 1b/2 trial showed the patient had no detectable circulating tumor cells (CTCs) or putative metastatic tumor cells in the peripheral blood and additional large reductions in CCR5 expression on cancer-associated cells at 11 weeks of treatment with leronlimab. This patient's data also demonstrated tumor shrinkage of >20% after just a few weeks of treatment. Additionally, data from the patient under the emergency IND protocol with HER2+ metastatic, stage 4, MBC showed no sign of new metastatic spots in the liver, lung and brain during the treatment with leronlimab. These data demonstrate remarkable improvements in patients living with metastatic breast cancer, a deadly disease that requires imminent new treatment options.
Also read @ #92 & forward.
https://worldwide.espacenet.com/publicationDe...mp;locale=
How is this not a phenominal BOOOOM !!!!
MGK has always clearly pointed out our metastatic triple-negative breast cancer (“mTNBC”) targets the 85% population pool.
While tNBC is the remaining 15%.
Well, 2021 Cytodyn filed too for tNBC.
We are on-deck for the entire apple !!
DETAILED DESCRIPTION
[0019] Although metastasis is the leading cause of death for patients with breast cancer, currently there are no treatments available that are directed to the metastatic process. Thus, better treatments for metastatic cancer, including metastatic breast cancer are needed. Presented herein are methods for treating a subject for metastatic breast cancer by administering to the subject an effective amount of a CCR5 binding agent, such as leronlimab.
0025] As shown in the Examples presented herein, data from the first patient in the Phase 1b/2 trial showed the patient had no detectable circulating tumor cells (CTCs) or putative metastatic tumor cells in the peripheral blood and additional large reductions in CCR5 expression on cancer-associated cells at 11 weeks of treatment with leronlimab. This patient's data also demonstrated tumor shrinkage of >20% after just a few weeks of treatment. Additionally, data from the patient under the emergency IND protocol with HER2+ metastatic, stage 4, MBC showed no sign of new metastatic spots in the liver, lung and brain during the treatment with leronlimab. These data demonstrate remarkable improvements in patients living with metastatic breast cancer, a deadly disease that requires imminent new treatment options.
Also read @ #92 & forward.
https://worldwide.espacenet.com/publicationDe...mp;locale=
How is this not a phenominal BOOOOM !!!!
(7)
(0)Scroll down for more posts ▼
